Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep;43(9):636-639.
doi: 10.1097/COC.0000000000000718.

Medical Cannabis in Cancer Patients: A Survey of a Community Hematology Oncology Population

David M Macari  1 , Bolanle Gbadamosi, Ishmael Jaiyesimi, Susanna Gaikazian
Affiliations

Medical Cannabis in Cancer Patients: A Survey of a Community Hematology Oncology Population

David M Macari et al. Am J Clin Oncol. 2020 Sep.

Abstract

Objectives: Cancer patients are using medical cannabis (MC) to address symptoms; however, little data exist to guide clinicians when counseling patients. We seek to define the patterns of MC use among cancer patients, as well as efficacy and safety of MC.

Materials and methods: Cancer patients attending oncology office visits at Beaumont Hospital, Michigan from July to December 2018 were anonymously surveyed. The survey included data regarding demographics, diagnosis, treatment, symptom burden, and MC use. Patients who reported MC use since their cancer diagnosis completed a section on patterns of use, efficacy, and safety.

Results: The response rate was 188 of 327 (57.5%). MC use was reported by 46 of 188 (24.5%). A median composite baseline symptom score ranging from 8 (best) to 32 (worst) was higher in patients using MC versus nonusers; 17.5 versus 14.4 (P<0.001). Pain was the symptom with the highest frequency of improvement 34/42 (81%), followed by appetite 34/44 (77.3%), and anxiety 32/44 (73%). MC improved the ability to tolerate treatment in 24/44 (54.5%). Cloudy thinking is the symptom that worsened the most 7/42 (16.7%), with decreased energy being experienced by 4/41 (9.8%) of the users.

Conclusions: MC was utilized by a significant portion of cancer patients in this sample, across age, diagnosis, stage, and treatment. Patients with a higher severity of baseline symptoms were more likely to use MC and report a favorable efficacy profile of MC. Minimal toxicity was reported in this cohort. Prospective studies are needed to define the efficacy and safety of MC.

PubMed Disclaimer

References

    1. Braun IM, Wright A, Peteet J, et al. Medical oncologists’ beliefs, practices, and knowledge regarding marijuana used therapeutically: a nationally representative survey study. J Clin Oncol. 2018;36:1957–1962.
    1. Minerbi A, Häuser W, Fitzcharles MA. Medical cannabis for older patients. Drugs Aging. 2019;36:39–51.
    1. Zylla D, Steele G, Eklund J, et al. Oncology clinicians and the Minnesota Medical Cannabis Program: a survey on medical cannabis practice patterns, barriers to enrollment, and educational needs. Cannabis Cannabinoid Res. 2018;3:195–202.
    1. Mersiades AJ, Stockler MR, Olver IN, et al. Medicinal cannabis for chemotherapy-induced nausea and vomiting: prescribing with limited evidence. Med J Aust. 2019;210:11–12.e1.
    1. Chawla D, Yang YC, Desrosiers TA, et al. Past-month cannabis use among U.S. individuals from 2002-2015: an age-period-cohort analysis. Drug Alcohol Depend. 2018;193:177–182.

MeSH terms